You are here:

Archived: buprenorphine transdermal patches (BuTrans)

Advice

Following a resubmission

buprenorphine transdermal patches (Butrans®) are not recommended for use within NHS Scotland for the treatment of severe opioid responsive pain conditions which are not adequately responding to non-opioid analgesics.

Clinical effectiveness has not been demonstrated in the patient population under consideration in the resubmission.

The licence holder has indicated their intention to resubmit.

Drug Details

Drug Name: buprenorphine transdermal patches (BuTrans)
SMC Drug ID: 234/06
Manufacturer: Napp Pharmaceuticals Ltd
Indication: Severe opioid responsive pain conditions which are not adequately responding to non-opioid analgesics.
BNF Category:
Sub Category: 4.7 Analgesics
Submission Type: Resubmission
Status: Not Recommended
Date Advice Published: 7 May 2007

Current Advice

Resubmission 12 January 2009

Archived Advice

Resubmission 11 August 2008
Full submission 13 February 2006

Back